Compare ADMA Biologics Inc (ADMA) vs Celsius Holdings, Inc. (CELH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ADMA Biologics Inc vs Celsius Holdings, Inc. — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.18B), while Celsius Holdings, Inc. trades at $28.08 (market cap $6.89B). The key difference: Celsius Holdings, Inc. is far larger — about 3.2× ADMA Biologics Inc's market cap. Which is the better fit depends on your goals.
| ADMA | CELH | |
|---|---|---|
Market Cap | $2.18B | $6.89B |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $64.86 |
52-Week Low | $7.60 | $23.77 |
Enterprise Value | $2.25B | $8.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.90, down 1.59% today, with strong profitability metrics including 64.71% gross margin and 41.9% ROE. Technical indicators show a bullish trend with support at $9-10, though RSI levels suggest overbought conditions. Recent earnings show mixed results with Q4 2025 beating expectations but Q1 and Q2 2026 missing estimates. The stock faces significant legal headwinds with multiple securities fraud lawsuits filed against the company.
Despite strong fundamentals and bullish analyst consensus (88.9% buy ratings), ADMA faces substantial legal risks from ongoing securities litigation that could impact shareholder value. The company's solid profit margins and growth trajectory provide upside potential, but investors should carefully weigh litigation risks against fundamental strength.
CELH trades at $27.77, up 16.83% in 24 hours, but technical indicators signal a bearish trend. The company reported Q2 2026 earnings of $0.36 per share, missing estimates, with revenue growth slowing to 11% year-over-year. Recent news includes an analyst downgrade and leadership changes amid an organizational realignment. Valuation metrics remain elevated with a P/E of 120.74 and P/S of 2.37.
The outlook is mixed: strong analyst consensus (95.65% buy ratings) and a $44.08 price target suggest upside, but risks include core brand weakness, margin pressure, and a pending legal investigation. Investors should weigh growth potential from Alani Nu and Rockstar integrations against execution challenges and high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →
